Amy Schumer, Ozempic, and GLP-1 Drugs: Separating Fact from Fiction

What Amy Schumer Actually Said About Ozempic

Amy Schumer did not quietly try a weight-loss drug and disappear from the conversation. She talked about it openly. In a 2023 interview with News Not Noise host Jessica Yellin, Schumer confirmed she had tried Ozempic and stopped because it made her feel "so sick." She did not frame the drug as dangerous for everyone, and she did not say women should avoid it. That distinction matters clinically.

Her exact words, in context

Schumer's description of her experience centered on one symptom: nausea severe enough to interfere with daily functioning. She described feeling ill in a way that was not tolerable for her. That is consistent with the pharmacology of semaglutide, a GLP-1 receptor agonist that slows gastric emptying and acts on brainstem nausea centers.

She also confirmed, separately and repeatedly, that she lives with endometriosis. In 2019, she was hospitalized and had her uterus removed due to endometriosis-related complications, while her ovaries were preserved. She has discussed this on social media, in interviews, and in her Netflix special.

Why the media got this wrong

The dominant misread of her story went in two directions. One camp framed her as rejecting GLP-1s because they are unsafe. The other framed her story as evidence that women who stop these drugs are simply not trying hard enough. Both framings ignore her specific medical context entirely.

The Clinical Reality: Why Women Experience More GLP-1 Nausea

Women are not just smaller men with different hormones. GLP-1 receptor agonists behave differently in female physiology, and nausea is the clearest example.

Gastric emptying and sex differences

Women have measurably slower baseline gastric emptying than men, a difference confirmed across multiple studies using scintigraphy. One gastroenterology review found that gastric half-emptying time averages roughly 109 minutes in healthy women versus 79 minutes in men. Semaglutide further slows gastric emptying as part of its mechanism. In a woman who already has slow gastric motility, that compounding effect can tip nausea from manageable to intolerable.

Trial data on sex-disaggregated nausea rates

The STEP 1 trial, the key phase 3 study of 2.4 mg semaglutide for weight management, enrolled a population that was approximately 75% female, which is actually more representative than most cardiovascular trials. Nausea was reported in 44.2% of participants in the semaglutide group versus 16.0% in placebo. The trial did not publish sex-disaggregated nausea rates as a primary endpoint, which is exactly the evidence gap women deserve to have filled.

Pooled analysis across the SUSTAIN series (the type 2 diabetes trials of semaglutide 0.5 mg and 1 mg) showed nausea rates roughly 10-13 percentage points higher in women than in men. That is not a small difference.

Estrogen's role

Estrogen modulates serotonin signaling in the gut and brainstem, both of which are involved in nausea pathways. During the luteal phase of the menstrual cycle, when progesterone peaks, gastric emptying slows further. A woman starting a GLP-1 agonist in her luteal phase may experience a worse first few weeks than someone who starts at a different point in her cycle. No current prescribing guideline addresses cycle timing for GLP-1 initiation. That is a gap.

Endometriosis: The Confounding Factor Almost Every Article Missed

Endometriosis affects roughly 1 in 10 women of reproductive age worldwide, and its GI manifestations are significant and underappreciated. Bowel endometriosis can cause nausea, bloating, diarrhea, and cramping, symptoms that overlap almost completely with GLP-1 side effects.

What endometriosis does to the gut

When endometrial-like tissue implants on the bowel, rectum, or surrounding structures, it triggers inflammation that alters gut motility and visceral sensitivity. A 2021 study in Fertility and Sterility found that women with endometriosis had significantly higher rates of irritable bowel syndrome-like symptoms compared to controls, including nausea.

For a woman like Schumer, who has confirmed endometriosis and had extensive surgery for it, baseline GI sensitivity is likely already elevated. Adding a drug that further slows gastric emptying into that physiological context is not the same clinical situation as prescribing semaglutide to a woman without GI pathology.

The surgical context changes her physiology

Schumer had her uterus removed but retained her ovaries. This means she is not surgically menopausal and still cycles hormonally. However, the inflammation and adhesions from endometriosis and its surgical management can alter abdominal anatomy and visceral nerve function in ways that are not fully reversed by surgery. Her experience of nausea on semaglutide is almost certainly a product of her specific post-surgical, endometriosis-affected GI tract, not a generalizable statement about what semaglutide does to all women.

The WomanRx Endometriosis-GLP-1 Consideration Framework

Before initiating a GLP-1 agonist in a woman with known or suspected endometriosis, a thoughtful prescriber should consider:

1. Baseline GI symptom burden (use a validated tool like the GSRS)
2. Prior bowel or pelvic surgery that may affect gastric motility
3. Current hormonal therapy that may interact with GLP-1 GI effects
4. Cycle phase at initiation (consider starting in the follicular phase)
5. A slower titration schedule than the standard manufacturer protocol

No guideline currently recommends this. It is clinical reasoning extrapolated from the underlying physiology, and women deserve to hear that distinction clearly.

Common Misinformation About Amy Schumer and GLP-1 Drugs

Let us go through the specific claims that circulated and assess each one against the evidence.

Misinformation #1: "She stopped because GLP-1 drugs are dangerous"

This is wrong. Schumer did not say the drug is dangerous. Nausea at the level she described is a known, expected, and for most people temporary side effect. The STEP 5 trial, a two-year extension study of semaglutide 2.4 mg, showed that nausea rates peak in the first 20 weeks and decline substantially thereafter in most participants. Stopping early because nausea is severe in the first weeks is a legitimate individual decision. It is not evidence that the drug is broadly dangerous.

Misinformation #2: "She stopped because she lost too much weight and looked sick"

This claim merged her story with the broader "Ozempic face" conversation in a way that misrepresented what she said. "Ozempic face," the facial volume loss associated with rapid weight loss on GLP-1 drugs, is a real aesthetic concern that dermatologists have documented. But Schumer's stated reason for stopping was nausea. Attributing her decision to cosmetic concerns rather than a GI side effect she explicitly named is a substitution of a story that fits cultural assumptions for the one she actually told.

Misinformation #3: "Her experience proves GLP-1 drugs don't work for women with endometriosis"

One person stopping one drug because of nausea proves nothing about a population. There are no published randomized controlled trials studying semaglutide or any GLP-1 agonist specifically in women with endometriosis. Some preliminary research suggests GLP-1 receptor activation may have anti-inflammatory effects that could theoretically be relevant to endometriosis pathophysiology, but this remains early-stage science without clinical trial confirmation. Schumer's individual experience cannot support a population-level conclusion in either direction.

Misinformation #4: "She was using Ozempic irresponsibly for cosmetic weight loss"

Ozempic (semaglutide 0.5 mg and 1 mg) is FDA-approved for type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. Wegovy (semaglutide 2.4 mg) is the FDA-approved formulation for chronic weight management, indicated for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. Off-label use of Ozempic for weight management is common and widely prescribed by physicians. Whether Schumer met clinical criteria for that use is her private medical information. Labeling any woman's use of a doctor-prescribed medication as "irresponsible" without knowledge of her medical chart is not journalism. It is speculation.

GLP-1 Drugs and Women's Health: The Bigger Picture

Schumer's story surfaced at a moment when GLP-1 agonists were moving from diabetes clinics into mainstream culture, and women were at the center of that shift.

Who is actually using these drugs

Women make up a disproportionate share of GLP-1 users for weight management. A 2023 KFF analysis found that among adults who reported taking a GLP-1 drug for weight loss, women outnumbered men. Women also carry a higher burden of the conditions these drugs treat: obesity affects women differently due to hormonal influences across the menstrual cycle, perimenopause, and menopause, and conditions like PCOS, hypothyroidism, and endometriosis compound metabolic risk.

PCOS and GLP-1 drugs

Polycystic ovary syndrome affects 6 to 12% of women of reproductive age in the United States and is closely linked to insulin resistance. GLP-1 agonists improve insulin sensitivity and have shown benefit in small trials for PCOS-related weight and metabolic markers. A 2022 meta-analysis in Fertility and Sterility found that GLP-1 agonists significantly reduced BMI, fasting insulin, and androgen levels in women with PCOS compared to placebo or metformin alone. This is a condition Schumer's story never touched, but it is where GLP-1 drugs may have some of their most meaningful clinical application in women's health.

Perimenopause and metabolic weight gain

Women entering perimenopause face a shift in fat distribution toward visceral fat, driven by declining estrogen. This visceral adiposity increases cardiometabolic risk independent of total body weight. GLP-1 agonists reduce visceral fat, and a subgroup analysis from STEP 1 confirmed meaningful reductions in waist circumference alongside total body weight. For perimenopausal women who find that standard dietary interventions no longer produce the same results they did in their 30s, GLP-1 therapy is a clinically grounded option, not a shortcut.

Pregnancy, Lactation, and Contraception: What Women Must Know

Any drug article for a women's health audience requires this section. GLP-1 agonists carry specific and serious considerations for women who are pregnant, trying to conceive, or breastfeeding.

Pregnancy: contraindicated

Semaglutide is contraindicated in pregnancy. Animal reproduction studies showed fetal harm at doses below the human therapeutic dose, including structural malformations and embryofetal mortality. Human data are limited to case reports and registry data, which are insufficient to establish safety. The FDA prescribing information for Wegovy states that the drug should be discontinued at least two months before a planned pregnancy. Tirzepatide (Mounjaro, Zepbound) carries the same contraindication.

If you are using a GLP-1 agonist and are not using effective contraception, this requires an immediate conversation with your prescriber. Women with PCOS who may have believed they were not ovulating regularly can experience restored ovulatory function with weight loss on GLP-1 therapy, which increases pregnancy risk if contraception is not in place. ACOG has noted this effect in guidance on GLP-1 use in women with obesity.

Lactation

Semaglutide has not been studied in breastfeeding women. It is unknown whether the drug is present in human milk. Given the lack of data and the theoretical risk to a nursing infant, GLP-1 agonists are generally not recommended during breastfeeding. A woman who is postpartum and breastfeeding should discuss the benefit-risk ratio with her clinician before initiating any GLP-1 therapy.

Contraception interactions

GLP-1 agonists slow gastric emptying, which can delay the absorption of oral medications, including oral contraceptive pills. A pharmacokinetic study of oral semaglutide (Rybelsus) found that co-administration with oral contraceptives was not clinically significant in that specific formulation, but injectable semaglutide's effect on gastric motility is relevant for any oral medication taken around the same time. Women on oral contraceptive pills who are also using injectable semaglutide should take their pill at a consistent time relative to meals and discuss any concerns with their prescriber.

Who This Is Right For and Who Should Think Carefully

GLP-1 agonists are not the right answer for every woman who wants to manage her weight. They are also not the wrong answer for every woman who has had a difficult experience with nausea.

Women who may benefit most

• Women with PCOS and insulin resistance, where GLP-1 drugs address the metabolic root
• Perimenopausal and postmenopausal women with visceral adiposity and elevated cardiometabolic risk
• Women with type 2 diabetes or prediabetes who also have a BMI of 27 or above
• Women who have tried structured lifestyle intervention for at least 12 months without achieving clinically meaningful weight reduction

Women who should approach with additional caution

• Women with pre-existing GI conditions including gastroparesis, inflammatory bowel disease, or bowel endometriosis
• Women with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (absolute contraindication per FDA labeling)
• Women who are pregnant, trying to conceive within two months, or breastfeeding
• Women with a history of pancreatitis (relative contraindication requiring individualized assessment)
• Women in early postpartum whose weight trajectory has not yet stabilized

Amy Schumer falls into the "additional caution" category because of her bowel endometriosis history. Her decision to stop was medically coherent. It was not a failure, and it was not a public health message against GLP-1 drugs.

A Note on Celebrity Health Narratives and Clinical Caution

WomanRx reviewer Dr. Elena Vasquez, MD, notes: "When a celebrity describes a drug side effect, we see two failure modes in the coverage that follows. The first is dismissal: 'she wasn't committed enough.' The second is overcorrection: 'this proves the drug is harmful.' Neither serves women who are trying to make an informed decision about their own bodies. What actually serves them is the physiology, the real trial data, and an honest acknowledgment of where the evidence runs out."

Celebrity health disclosures can push real women toward or away from treatments based on a single person's experience in a body with a specific medical history. Schumer's nausea was real. Her endometriosis is real. Her decision to stop Ozempic was hers to make. None of that tells you what semaglutide will do in your body, with your hormonal status, your GI history, your life stage, and your metabolic needs.

Use her story as an opening to ask better questions of your prescriber, not as a conclusion.